Vir Biotechnology, Inc. (VIR)
VIRNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$13.53
+1.32 (+10.82%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $2.34bn
- P/E
- –
- EPS, last 4 quarters
- $-1.26
- Dividend yield
- –
- Day range
- –
- 52-week range
- $4.82 to $12.45
- Average volume
- 2.02m
- Previous close
- $12.21
Analysts
8 coveringBuy8 buy, 0 hold, 0 sell
Targets a year out average $21.57, +59.4% from here
Earnings
next estimate $-0.4700Next report
Dec 2025
+26.2%
Mar 2026
–
Jun 2026
-43.4%
Sep 2026
+28.8%
estimate reported, and the surprise
Financials
| Quarter | Jun 2025 | Sep 2025 | Dec 2025 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $1.21m | $240.0k | $64.07m | $238.95m |
| Gross profit | $1.20m | $251.0k | $64.04m | $238.95m |
| Operating income | -$118.42m | -$173.44m | -$47.92m | $73.47m |
| Net income | -$110.96m | -$163.14m | -$42.92m | $80.08m |
Last four quarters: revenue $304.47m, margin -77.8%, free cash flow -$193.57m
News
8 latest- Vir Biotechnology, Inc. Reports 44% Response Rate in Phase 3 ECLIPSE 1 Trial and Week 96 SOLSTICE DataFintel · 11 hours ago
- Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain RTTNews · 12 hours ago
- Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should KnowZacks · 17 hours ago
- Vir's Hepatitis Delta Combo Shows Sustained Viral Suppression; Shares Rise 15% Premarket RTTNews · 21 hours ago
- Vir Bio (VIR) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- What Vir Biotechnology (VIR) Said on Its Q3 Earnings CallMarketBeat · 5 days ago
- Vir Biotechnology, Inc. Reports Third Quarter 2026 Financial ResultsFintel · 5 days ago
- Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue EstimatesZacks · 5 days ago
The company
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. Vir Biotechnology has exclusive rights to the universal PRO-XTEN masking platform for oncology and infectious disease. PRO-XTEN is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- vir.bio
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.